Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $850.00 Price Target at JPMorgan Chase & Co.

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective cut by stock analysts at JPMorgan Chase & Co. from $950.00 to $850.00 in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage presently has an “overweight” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s price target would suggest a potential upside of 35.45% from the stock’s previous close.

REGN has been the topic of several other research reports. Oppenheimer reiterated an “outperform” rating and issued a $865.00 price objective (up from $750.00) on shares of Regeneron Pharmaceuticals in a research note on Monday, February 2nd. Evercore upped their price objective on shares of Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the company an “outperform” rating in a research note on Thursday, January 22nd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $800.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Thursday, April 23rd. Wall Street Zen upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Finally, Morgan Stanley upped their price objective on shares of Regeneron Pharmaceuticals from $769.00 to $796.00 and gave the company an “equal weight” rating in a research note on Friday, April 10th. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have given a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $806.57.

Regeneron Pharmaceuticals Trading Down 10.1%

Shares of NASDAQ:REGN traded down $70.70 during mid-day trading on Monday, hitting $627.55. The stock had a trading volume of 1,285,565 shares, compared to its average volume of 757,008. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.96 and a current ratio of 3.57. The company has a market cap of $66.34 billion, a PE ratio of 15.24, a P/E/G ratio of 1.55 and a beta of 0.30. Regeneron Pharmaceuticals has a 12-month low of $476.49 and a 12-month high of $821.11. The company’s 50 day moving average is $744.69 and its 200-day moving average is $746.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, beating the consensus estimate of $8.91 by $0.56. The business had revenue of $3.61 billion during the quarter, compared to the consensus estimate of $3.48 billion. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The firm’s quarterly revenue was up 19.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $8.22 EPS. On average, sell-side analysts predict that Regeneron Pharmaceuticals will post 37.1 EPS for the current year.

Insiders Place Their Bets

In related news, Director Huda Y. Zoghbi sold 1,638 shares of the firm’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $781.33, for a total value of $1,279,818.54. Following the transaction, the director directly owned 1,703 shares in the company, valued at approximately $1,330,604.99. This trade represents a 49.03% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction on Friday, May 1st. The shares were sold at an average price of $705.24, for a total transaction of $70,524.00. Following the completion of the transaction, the director owned 17,503 shares in the company, valued at $12,343,815.72. The trade was a 0.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is currently owned by company insiders.

Institutional Trading of Regeneron Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of REGN. WPG Advisers LLC grew its position in Regeneron Pharmaceuticals by 312.5% in the 4th quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 25 shares during the last quarter. SHP Wealth Management acquired a new stake in Regeneron Pharmaceuticals in the 4th quarter worth $26,000. Titan Wealth CI Ltd acquired a new stake in Regeneron Pharmaceuticals in the 4th quarter worth $29,000. Board of the Pension Protection Fund acquired a new stake in Regeneron Pharmaceuticals in the 4th quarter worth $31,000. Finally, Kemnay Advisory Services Inc. acquired a new stake in Regeneron Pharmaceuticals in the 4th quarter worth $31,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Negative Sentiment: Regeneron’s phase 3 melanoma trial for fianlimab missed its main goal, weakening confidence in a high-profile pipeline asset and contributing to analyst downgrades. Reuters article
• Neutral Sentiment: Citigroup reaffirmed its neutral rating on REGN but cut its price target to $700 from $900, signaling a more cautious valuation view. Tickerreport article
• Neutral Sentiment: Leerink Partners also reaffirmed a market perform rating and lowered its target to $641 from $792, reflecting reduced expectations after the trial setback. Benzinga article
• Positive Sentiment: Regeneron announced a strategic collaboration with Parabilis Medicines to develop novel antibody-Helicon conjugates, a pipeline-expanding deal that could eventually generate significant milestone payments and royalties. Yahoo Finance article

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.